212061-57-9

Upstream product

• 107-21-1 ethylene glycol 
• 817623-11-3 2,2'-anhydro-1-[2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-β-D-arabinofuranosyl-5-methyluridine] 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 1463-10-1 5-Methyluridine 
• 7790-21-8 potassium metaperiodate 
• 212061-56-8 2'-O-Allyl-5'-O-dimethoxytrityl-5-methyluridine 
• 7529-22-8 4-methylmorpholine N-oxide 

Downstream Products

• 1412707-66-4 2'-O-{2-[3-(7,8-didehydro-1,2:5,6-dibenzocyclooctynyl)oxyamido]ethyl}-5'-O-(4,4'-dimethoxytrityl)-5-methyluridine 3'-O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite 
• 1412707-61-9 2'-O-{2-[3-(7,8-didehydro-1,2:5,6-dibenzocyclooctynyl)oxyamido]ethyl}-5'-O-(4,4'-dimethoxytrityl)-5-methyluridine 
• 1263796-39-9 C₃₃H₃₅N₅O₈ 
• 242147-79-1 2'-O-[2-(amino)ethyl]-5'-O-(4,4'-dimethoxytrityl)-5-methyluridine 
• 1263796-38-8 C₃₄H₃₈N₂O₁₁S 

Relevant academic research and scientific papers

OLIGONUCLEOTIDE LIGATION

A method for joining oligonucleotides. The method includes joining together one or more oligonucleotides by reacting an alkyne group lined to an oligonucleotide with an azide group linked to an oligonucleotide to form a triazole linkage. The alkyne group is a strained alkyne group. The method can include ligating together ends of one or more oligonucleotides or cross-linking strands of an oligonucleotide duplex. The methods described allow oligonucleotide strands to be ligated together without the need for a ligase enzyme.

AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Nucleosidic monomers and oligomeric compounds prepared therefrom are provided which have increased nuclease resistance, substituent groups (such as 2′-aminooxy groups) for increasing binding affinity to complementary strand, and regions of 2′-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.

Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom

Nucleosidic monomers and oligomeric compounds prepared therefrom are provided which have increased nuclease resistance, substituent groups (such as 2′-aminooxy groups) for increasing binding affinity to complementary strand, and regions of 2′-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.

Oligonucleotide analogs having modified dimers

Modified dimers having a ribose sugar moiety in the 5′ nucleoside and a 2′ modified sugar in the 3′ nucleoside are provided. The modified dimers are useful in the preparation of oligonucleotide analogs having enhanced properties compared to native oligonucleotides, including increased nuclease resistance, enhanced binding affinity and improved protein binding.

Aminooxy-modified oligonucleotides and methods for making same

Oligonucleotides and other macromolecules are provided which have increased nuclease resistance, substituent groups (such as 2''-aminooxy groups) for increasing binding affinity to complementary strand, and subsequences of 2''-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.

2'-O-aminooxy-modified oligonucleotides

Nucleotide compositions containing aminooxy moieties are provided. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the nucleoside moieties of the oligonucleotide is modified to include an aminooxy moiety.